Heparin Market Projected to Grow $7.4 Billion by 2026 | Key Players – GlaxoSmithKline plc; Pfizer, Inc.; Baxter; Leo Pharma A/S; Sanofi; and Teva Pharmaceutical Industries Ltd.
The global heparin market size is expected to reach USD 7.4 billion by 2026, according to a new report by Grand View Research, Inc. It is projected to register a CAGR of 1.6% during the forecast period. Rising prevalence cardiovascular disorders, deep vein thrombosis, and renal diseases among other chronic diseases is expected to boost the growth.
According to the data published in the American Heart Association, in 2018, approximately 92.1 million American adults were living with some form of cardiovascular diseases. Coronary heart disease is one of the leading cause of deaths in U.S. Furthermore, it was estimated that more than 23.6 million deaths will be observed by 2030 due to cardiovascular diseases.
Increasing demand for transfusion of blood, blood components, and plasma derivatives during surgical procedures, treatment of infectious diseases, and increasing survival rate are high impact rendering drivers for growth of the heparin market during the forecast period. Increasing demand for RBCs and platelets by various hospital divisions and clinics is expected to have a positive impact on the growth.
Request a Sample Copy of the Global Heparin Market Research Report @ www.grandviewresearch.com/industry-analysis/heparin-market/request/rs1
Growing geriatric population is anticipated to propel the market growth. According to an article published in 2018 in the United States Census Bureau, it is estimated that by 2035, population aged 65 years and above is expected to reach 78 million whereas children under the age of 18 may reach around 76.7million.
Rising incidence of immunological diseases, thrombosis, and hemostasis is likely to result in high demand for therapeutic plasma proteins. Manufacturing of plasma proteins led to an increase in the demand for purified plasma, further expected to fuel the market over the forecast period.
Further key findings from the study suggest:
- Low molecular weight heparin led the type segment in 2018 owing to its more predictable anticoagulant effect
- In 2018, ultra-low molecular weight heparin was estimated to be the fastest growing segment, owing to commercialization of enhanced version of products with improved pharmacological effects
- Subcutaneous route of administration led the market in 2018 and is estimated to be the fastest growing segment over the forecast period due to ease of administration
- Coronary artery disease was considered to be the largest application segment in 2018 and venous thromboembolism is projected to be the fastest growing segment in near future
- In 2018, outpatient led the end use segment and was estimated to register the fastest growth in the forthcoming years
- North America held the largest market share in 2018 owing to increasing prevalence of cardiovascular disorders and sports injuries. Asia Pacific is estimated to be the fastest growing segment over the forecast period
- Some of the key companies operating in the heparin market are GlaxoSmithKline plc; Pfizer, Inc.; Baxter; Leo Pharma A/S; Sanofi; Dr. Reddy’s Laboratories Ltd.; Aspen Holdings; B. Braun Medical Inc.; Fresenius SE & Co. KGaA; and Teva Pharmaceutical Industries Ltd
Have Any Query? Ask Our Experts @ www.grandviewresearch.com/inquiry/476/ibb
Grand View Research has segmented the global heparin market based on type, route of administration, application, end use, and region:
Heparin Type Form Outlook (Revenue, USD Million, 2014 – 2026)
- Low Molecular Weight Heparin
- Ultra-low Molecular Weight Heparin
- Unfractionated Heparin
Heparin Route of Administration Outlook (Revenue, USD Million, 2014 – 2026)
- Intravenous
- Subcutaneous
Heparin Application Form Outlook (Revenue, USD Million. 2014 – 2026)
- Venous Thromboembolism
- Atrial Fibrillation
- Renal Impairment
- Coronary Artery Disease
- Others
Heparin End Use Outlook (Revenue, USD Million, 2014 – 2026)
- Outpatient
- Inpatient
Heparin Regional Outlook (Revenue, USD Million, 2014 – 2026)
- North America
- U.S.
- Canada
- Europe
- U.K.
- Germany
- France
- Italy
- Spain
- Russia
- Asia Pacific
- Japan
- China
- India
- South Korea
- Australia
- Singapore
- Latin America
- Brazil
- Mexico
- Argentina
- Middle East & Africa
- South Africa
- UAE
- Saudi Arabia
Browse Related Report:
Gastrointestinal Therapeutics Market: www.grandviewresearch.com/industry-analysis/gastrointestinal-therapeutics-market
Pediatric Vaccines Market: www.grandviewresearch.com/industry-analysis/pediatric-vaccine-market
About Grand View Research
Grand View Research provides syndicated as well as customized research reports and consulting services on 46 industries across 25 major countries worldwide. This U.S.-based market research and consulting company is registered in California and headquartered in San Francisco. Comprising over 425 analysts and consultants, the company adds 1200+ market research reports to its extensive database each year. Supported by an interactive market intelligence platform, the team at Grand View Research guides Fortune 500 companies and prominent academic institutes in comprehending the global and regional business environment and carefully identifying future opportunities.
Media Contact
Company Name: Grand View Research, Inc.
Contact Person: Sherry James, Corporate Sales Specialist – U.S.A.
Email: Send Email
Phone: 1-415-349-0058, Toll Free: 1-888-202-9519
Address:201, Spear Street, 1100
City: San Francisco
State: California
Country: United States
Website: www.grandviewresearch.com/industry-analysis/heparin-market